Jefferies Starts Atara Biotherapeutics (ATRA) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Atara Biotherapeutics (ATRA) Reports Q3 Loss of $4.20
November 12, 2014 6:36 AM ESTAtara Biotherapeutics (NASDAQ: ATRA) reported Q3 EPS of ($4.20), versus ($2.59) reported last year.
For earnings history and earnings-related data on Atara Biotherapeutics (ATRA) click here.
... MoreGoldman Sachs Starts Atara Biotherapeutics (ATRA) at Neutral
November 10, 2014 7:20 AM ESTGoldman Sachs initiated coverage on Atara Biotherapeutics (NASDAQ: ATRA) with a Neutral rating and a price target of $30.00.
Analyst Navdeep Singh said, "Atara is an early-stage biotech developing (1) PINTA 745 for kidney dialysis patients who suffer from muscle wasting and (2) STM 434 for advanced ovarian... More
